Quantum BioPharma Appoints Dr. Napoli as Lucid-MS Phase 2 PI, IND Submission Imminent
Quantum BioPharma has appointed Dr. Salvatore Napoli as Principal Investigator for its planned Phase 2 clinical trial of Lucid-21-302 (Lucid-MS) targeting demyelination in multiple sclerosis. The company plans to submit an IND application to the FDA in the coming weeks to evaluate Lucid-MS efficacy, safety and tolerability.
1. Appointment Details
Quantum BioPharma has named Dr. Salvatore Napoli—an internationally recognized neurologist with over 20 years of clinical and research experience in multiple sclerosis—as Principal Investigator. Dr. Napoli leads the Neurology Center of New England and the MS Center of New England, completed fellowship training at Brigham and Women’s Hospital and has held academic appointments at Harvard Medical School, serving on numerous MS clinical trials.
2. IND Submission and Trial Design
The company intends to submit an Investigational New Drug application for Lucid-MS to the U.S. FDA in the coming weeks. Subject to regulatory clearance, the planned Phase 2 trial will assess the efficacy, safety and tolerability of Lucid-MS in people with multiple sclerosis.
3. Lucid-MS Candidate Profile
Lucid-MS is a first-in-class, non-immunomodulatory neuroprotective new chemical entity designed to target demyelination and promote remyelination. Preclinical models have shown Lucid-MS can prevent and reverse myelin sheath damage, addressing a critical unmet need in MS treatment.